Skip to main content
. Author manuscript; available in PMC: 2025 Jun 3.
Published in final edited form as: Mol Cancer Ther. 2024 Dec 3;23(12):1801–1814. doi: 10.1158/1535-7163.MCT-24-0369

Figure 2. RB1 is required for full response to CDK4/6 and MEK inhibition in both cell culture and xenograft fibrosarcoma models.

Figure 2.

A. Immunoblot analysis for E2F target proteins in HT1080 and MIA PaCa-2-sgCtrl/sgRB cells treated with DMSO or CDK4/6i (Palbociclib, 100 nM) and MEKi (Trametinib, 25 nM) in combination for 48 h. B. BrdU incorporation was assessed in HT1080 and MIA PaCa-2-sgCtrl/sgRB cells treated with DMSO or CDK4/6i (Palbociclib, 100 nM) and MEKi (Trametinib, 25 nM) in combination at indicated concentrations for 72 h. Data shown as mean ± standard deviation (SD). C. Live-cell imaging tracking HT1080 or MIA PaCa-2-sgCtrl/sgRB cell growth when treated with DMSO or CDK4/6i (Palbociclib, 100 nM) and MEKi (Trametinib, 25 nM) in combination at indicated concentrations for 96 h. Data displayed as mean ± SD. D. Clonogenic assay in HT1080 or MIA PaCa-2-sgCtrl/sgRB cells treated with DMSO or CDK4/6i (Palbociclib, 100 nM) and MEKi (Trametinib, 25 nM) in combination for 14 days. E. HT1080-sgCtrl/sgRB-injected xenograft models treated with vehicle or CDK4/6i (Palbociclib, 100 mg/kg) and MEKi (Trametinib, 0.5 mg/kg) in combination once tumor volume reached 200 mm3. Relative tumor volume was determined every 24 h. Data shown as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 as determined by two-way ANOVA. F. HT1080-sgCtrl/sgRB xenograft tumors from vehicle and CDK4/6i (Palbociclib, 100 mg/kg) and MEKi (Trametinib, 0.5 mg/kg)-treated mice stained for pRB (S807/811), Ki67 and by H&E. Representative images are displayed (scale bar = 100 μm).